Distal Ischemic Stroke Treatment With Adjustable Low-profile Stentriever

Ischemic Stroke Clinical Trial

— DISTALS  

Official title:

Distal Ischemic Stroke Treatment With Adjustable Low-profile Stentriever

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05152524
• Other study ID #: CLN-TR13-001
• Status: Recruiting
• Phase: N/A
• Start date: March 25, 2022
• Est. completion date: August 2024

Study information

• Verified date: March 2024
• Source: Rapid Medical
• Contact: Walid Haddad, Dr.
• Phone: +972 72 2503331
• Email: walid[@]rapid-medical.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the DISTALS Study is to evaluate the safety and effectiveness of the Tigertriever 13 Revascularization Device in restoring blood flow in the neurovasculature by removing thrombus in patients presenting within 24 hours of onset with an ischemic stroke with disabling neurological deficits due to a primary distal vessel occlusion (DVO), as compared to medical management.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 168
• Est. completion date: August 2024
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 85 Years

Eligibility

Inclusion Criteria:

1. Age 18-85 years old.

2. Pre-stroke mRS =2.

3. Disabling presenting deficits that localize to the territory of the distal vessel occlusion. Disabling deficits are deficits that, if unchanged, would prevent the subject from performing basic activities of daily living (i.e., bathing, ambulating, toileting, hygiene, and eating) or returning to work.

4. NIHSS 4-24, or NIHSS 2-24 for patients with aphasia and/or hemianopia.

5. Perfusion lesion (Tmax >4.0 seconds) volume =10 cc on CTP or MR PWI within the territory of the anterior cerebral artery (ACA) segments, a non-dominant or co-dominant M2 middle cerebral artery (MCA) segment, an M3 MCA, or the posterior cerebral artery (PCA) segments.

6. Occluded distal vessel diameter =1.5 mm as measured on CTA or MRA.

7. Ischemic core lesion (rCBF<30% on CTP or ADC <620 on MR DWI) in =50% of the perfusion lesion volume.

8. Study treatment can be initiated within 24 hours of last known well time (last known time without current stroke symptoms).

9. Signed informed consent by patient or legally authorized representative.

10. Subject is not eligible for intravenous thrombolysis within 3 hours from stroke onset per FDA label and American Heart Association/American Stroke Association national guidelines. (Note: administration of intravenous thrombolytics should not be avoided or delayed in order to achieve participation in this study.)

Exclusion Criteria:

1. Evidence of acute brain hemorrhage on CT and/or MRI at admission.

2. Use of any other intra-arterial (IA) recanalization device prior to the Tigertriever 13 in the target vessel, including aspiration catheter.

3. The DVO is a secondary distal occlusion that occurred during a large vessel occlusion (LVO) thrombectomy procedure.

4. Excessive tortuosity or stenosis that is anticipated to prevent placement of the microcatheter in the target vessel. Tortuosity or stenosis will be determined on CTA or MRA prior to randomization.

5. Evidence of tandem occlusion in the cervical internal carotid artery (ICA), intracranial ICA, M1 MCA, dominant M2 MCA, vertebral artery (VA) or basilar artery (BA) on CTA or MRA.

6. Evidence of dissection in the extra or intracranial cerebral arteries.

7. Evidence of bilateral acute stroke or acute stroke in multiple territories (e.g., bilateral anterior circulation, anterior/posterior circulation).

8. Prior stroke in the last 3 months.

9. Anticipated inability to obtain 3-month follow-up assessments.

10. Females who are pregnant or breastfeeding.

11. Renal failure with serum creatinine >3.0 or Glomerular Filtration Rate (GFR) <30.

12. Pre-procedural severe sustained hypertension with SBP >220 and/or DBP >120.

13. Pre-procedural glucose <50 mg/dl (2.78 mmol/L) or >400 mg/dl (22.20 mmol/L).

14. Pre-procedural coagulation factor deficiency or oral anti-coagulant therapy with an international normalized ratio (INR) of more than 1.7.

15. Treatment with heparin within 48 hours with a partial thromboplastin time more than two times the laboratory normal.

16. Treatment with a direct oral anticoagulant (DOAC) within 48 hours.

17. Platelet count of less than 50,000/uL.

18. History of severe allergy to contrast medium, nickel, or Nitinol.

19. Known current use of cocaine at time of treatment.

20. Known or suspected cerebral vasculitis.

21. Known hemorrhagic diathesis.

22. Aneurysm in target vessel.

23. Intracranial tumor (apart from small meningioma, =2 cm in diameter).

24. Ongoing seizure due to stroke.

25. Evidence of active systemic infection.

26. Known cancer with metastases.

27. Suspicion of aortic dissection, septic embolus, or bacterial endocarditis.

28. Subject already participating in another study of an investigational treatment device or treatment.

Related Conditions & MeSH terms

• Cerebral Infarction
• Ischemia
• Ischemic Stroke
• Neovascularization
• Neovascularization, Pathologic
• Stroke

Intervention

Device:
• Tigertriever 13
patients presenting within 24 hours of onset with an ischemic stroke with disabling neurological deficits due to a primary distal vessel occlusion (DVO) will be treated with the Tigertriever 13 device.

Locations

Country	Name	City	State
Belgium	CUB Hôpital Erasme	Brussels
Germany	University Hospital Knappschaftskrankenhaus	Bochum
Germany	Alfreid Krupp	Essen
Germany	Universitätsklinikum Schleswig-Holstein	Kiel
Germany	St. Lukas hospital, Radprax	Solingen
Sweden	Orebro University Hospital	Orebro
United States	University of Buffalo	Buffalo	New York
United States	Providence Health	Fullerton	California
United States	Corewell Health (Spectrum)	Grand Rapids	Michigan
United States	Valley Baptist Medical Center	Harlingen	Texas
United States	Lakewood Regional Medical Center	Los Angeles	California
United States	WellStar Research Institute	Marietta	Georgia
United States	Advocate Aurora Research Institute,	Milwaukee	Wisconsin
United States	Mount Sinai	New York	New York
United States	NYU Langone Health	New York	New York
United States	Thomas Jefferson University	Philadelphia	Pennsylvania
United States	Honor Health	Phoenix	Arizona
United States	Texas Stroke Institute	Plano	Texas
United States	Stony Brook University	Stony Brook	New York
United States	Los Robles	Thousand Oaks	California
United States	Mercy Health	Toledo	Ohio
United States	Munson Medical Center	Traverse City	Michigan
United States	Carondelet St. Jospeh's Hospital	Tucson	Arizona

Sponsors (1)

Lead Sponsor	Collaborator
Rapid Medical

Countries where clinical trial is conducted

United States,  Belgium,  Germany,  Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Successful reperfusion (CTP or MR PWI*) without sICH**.	*Successful reperfusion is defined as >50% reduction in substantial hypoperfusion (Tmax >4 seconds) volume between baseline and 24 ±6 hours of randomization.; **sICH shall be defined as any parenchymal hematoma type 2, remote intracerebral hemorrhage, subarachnoid hemorrhage, or intraventricular hemorrhage that is the predominant cause of =4 point NIHSS deterioration at 24 ±6 hours of randomization.	24±6 Hours post randomization
Secondary	All cause mortality at 90 days.	All cause mortality at 90 days.	90 days post randomization.
Secondary	Any asymptomatic intracranial hemorrhage within 24±6 hours of randomization.	Any asymptomatic intracranial hemorrhage within 24±6 hours of randomization.	24±6 hours of randomization.
Secondary	Device/procedure related serious adverse events (SAEs).	Device/procedure related serious adverse events (SAEs).	90 days post randomization.
Secondary	Unanticipated adverse device effect (UADEs).	Unanticipated adverse device effect (UADEs).	During procedure
Secondary	Volume of penumbral tissue salvaged at 24±6 hours of randomization (CTP or MR DWI/PWI).	Volume of penumbral tissue salvaged at 24 ±6 hours of randomization (CTP or MR DWI/PWI).	24±6 hours post randomization.
Secondary	Successful reperfusion at 24 hours, defined as >50% reduction in substantial hypoperfusion (Tmax >4 seconds) volume between baseline and 24 ±6 hours of randomization (assessed in both Treatment and Control arms).	Successful reperfusion at 24 hours, defined as >50% reduction in substantial hypoperfusion (Tmax >4 seconds) volume between baseline and 24 ±6 hours of randomization (assessed in both Treatment and Control arms).	24±6 hours post randomization
Secondary	Successful reperfusion (eTICI =2b50) rate in the distal occluded vessel after Tigertriever 13 mechanical thrombectomy (assessed in Treatment arm only).	Successful reperfusion (eTICI =2b50) rate in the distal occluded vessel after Tigertriever 13 mechanical thrombectomy (assessed in Treatment arm only).	24±6 hours Post procedure
Secondary	modified Rankin Scale (mRS) score	Level of global disability at 90 days measured by the modified Rankin Scale (mRS) shift (tetrachotomized: 0, 1, 2, 3-6). Minimum score: 0; Maximum score: 6. Lower scores reflects a better clinical outcome, and higher scores reflects worse clinical outcome.	90 days post randomization
Secondary	National Institutes of Health Stroke Scale (NIHSS) shift	NIHSS change from Baseline to Day 4. Minimum score: 0; Maximum score: 42. Lower scores reflects a better clinical outcome, and higher scores reflects worse clinical outcome.	4 days post procedure
Secondary	EQ-5D score	Health-related quality of life at 90 days - EQ-5D. Minimum score: 1; Maximum score: 9. Lower scores reflects a better clinical outcome, and higher scores reflects worse clinical outcome.	90 days post randomization
Secondary	MoCA: Montreal Cognitive Assessment	Cognitive function at 90 days. Minimum score: 0; Maximum score: 30. Higher scores reflects a better clinical outcome, and Lower scores reflects worse clinical outcome.	90 days post randomization